Linezolid concentrations in infected soft tissue and bone following repetitive doses in diabetic patients with bacterial foot infections.
Linezolid concentrations in infected soft tissue and bone following repetitive doses in diabetic patients with bacterial foot infections.
复制标题
患有细菌性足部感染的糖尿病患者重复服用利奈唑胺后，感染软组织和骨骼中的利奈唑胺浓度。
DOI：
10.1016/j.ijantimicag.2010.03.007
复制
发表时间：
2010
影响因子：
10.8
通讯作者：
C. Joukhadar
中科院分区：
文献类型：
--
作者：
F. Traunmüller;M. Schintler;S. Spendel;M. Popovic;O. Mauric;E. Scharnagl;C. Joukhadar
The present study aimed at assessing unbound extracellular concentrations of linezolid in inflamed soft tissue and bone of diabetic patients suffering from severe bacterial foot infections. Linezolid was administered intravenously twice daily at a dosage of 600mg. At steady-state conditions, the microdialysis technique was utilised to sample serially interstitial space fluid from inflamed subcutaneous adipose tissue and metatarsal bone from 0–8h post dose in three representative patients. Mean peak concentrations of free linezolid in plasma, healthy subcutis, inflamed subcutis and cancellous bone were 16.6±3.0, 15.5±2.5, 15.8±2.8 and 15.1±4.1mg/L, respectively. The degree of tissue penetration as expressed by the ratio of the area under the concentration–time curve of free linezolid from 0–12h (fAUC0–12) in tissue to the fAUC0–12in plasma was 1.32±0.09, 1.12±0.22 and 1.09±0.11 for healthy subcutis, inflamed subcutis and bone, respectively. Based on currently available pharmacokinetic/pharmacodynamic targets, we conclude that linezolid administered at 600mg twice daily may be considered an effective treatment in diabetic patients suffering from bacterial foot infection complicated by osteomyelitis.
